HBAN — Huntington Bancshares Incorporated

The tape feels cautious, not panicked: price is below short- and medium-term moving averages and RSI is soft, while the 3.68% dividend and 1.0x book value provide a floor. Sentiment is mixed because Q2 2026 beat expectations and Wells Fargo initiated with a Buy and $23 target, but BofA downgraded to Hold and the FMP consensus label is still Hold. The consensus price target near $20.33 implies meaningful upside, yet the market is waiting for proof that net interest margin pressure has peaked.

Revenue was roughly flat through 2024-2025, growing only 2-6% YoY, then inflected sharply: Q1 2026 revenue rose 26% YoY and Q2 2026 rose 38% YoY to $4.17B. That acceleration coincides with a large balance-sheet step-up from ~$225B of assets at year-end 2025 to ~$285B in Q1 2026, so much of the growth appears inorganic or balance-sheet-led rather than purely organic. Earnings are choppier: Q3 2025 net income was $629M, Q4 2025 was $519M, Q1 2026 was $523M, and Q2 2026 jumped to $727M. Operating margins have ranged from 17.0% to 23.7% without a clear upward trend, and per-share earnings are roughly flat: Q1 2026 EPS of $0.25 was below Q1 2025's $0.34, while Q2 2026 EPS of $0.38 was only 12% above Q2 2025's $0.34. This is an inflection in revenue, not yet in per-share earnings.

As of 2026-08-27, HBAN is fairly valued, not cheap: it trades at 12.4x TTM EPS of $1.232, essentially in line with its own 5-year average P/E of 12.41, and at 1.01x book value and 2.36x sales versus a 2.30x 5-year average P/S. A 3.68% dividend yield adds support. The apparent bargain disappears when quality is considered: ROE is only 9.1% and ROIC is negative, so 1.0x book is not automatically cheap. Using FMP's forward EPS estimate of $1.381, the forward P/E is about 12.2x; the research brief's $1.90 EPS guidance would imply a much cheaper multiple, but that guidance is not supported by reported 2026 quarterly EPS.

The stock is pricing in no real per-share growth. Revenue grew 26-38% in early 2026, but TTM EPS is actually below the FY2025 reported EPS of about $1.39, and Q1 2026 EPS declined year over year. At 12.2x forward consensus EPS, the market is treating HBAN as a stodgy average-ROE regional bank rather than a growth story. If management converts the larger balance sheet into consistent $0.38-$0.40 quarters, the multiple can re-rate toward 14x, which would put the stock in the $19-$20 range. If margin pressure persists and EPS stays near $1.30-$1.38, $16.86 is roughly fair value.

As of 2026-08-27, RSI-14 was 38.3, weak but not oversold. HBAN was 3.1% below its 20-day SMA, 4.0% below its 50-day SMA, and only 0.6% below its 200-day SMA. That is a mild short-term downtrend sitting right on the long-term trendline, not a confirmed breakdown. With the 52-week range at $14.89-$19.46, the stock is in the lower third of its range. Timing implication: no urgent buy signal; a reclaim of the 50-day or an RSI push above 50 would be more constructive, while the $15-$16 zone looks like a stronger value support area.

• Persistent deposit-cost pressure and deposit beta headwinds across regional banks are squeezing net interest margins.
• The rate path is two-sided: higher-for-longer supports asset yields but keeps funding costs elevated, while rate cuts could relieve deposit costs but reprice loans down.
• Regional-bank regulatory scrutiny and capital requirements remain a live factor, especially after the 2026 balance-sheet expansion.
• Credit cycle risk is elevated in commercial real estate and consumer portfolios; a downturn would force higher provision expense.

• Q3 2026 earnings on 2026-10-16; consensus EPS around $0.39 and any updated NII/margin guidance will be the main catalyst.
• Evidence that deposit costs are peaking and net interest margin is stabilizing.
• Texas expansion execution, including the UT Athletics partnership and Broadway in Austin sponsorship, building a faster-growth franchise.
• Analyst actions: Wells Fargo initiated with Buy and $23 target, and the consensus target near $20.33 implies upside if sentiment improves.

• Net interest margin compression could be worse or longer-lasting than expected if deposit costs keep rising.
• The large 2026 balance-sheet expansion may fail to deliver meaningful EPS accretion, especially if it was dilutive.
• Credit deterioration in consumer, commercial, or CRE portfolios could hit provisions and earnings.
• Sub-10% ROE and negative ROIC mean the bank is not compounding capital efficiently; if that doesn't improve, 1.0x book is not a bargain.

HBAN is a reasonable income-oriented investment around $16.86, not a high-conviction growth story. The stock offers a covered 3.68% dividend, trades at 12.4x earnings and 1.0x book, and has a real path to $18-$20 if deposit costs stabilize and the larger 2026 franchise starts showing up in per-share earnings. The main risk is that revenue growth remains inorganic and ROE stays in the 9% range, which would keep the stock range-bound. Overall, the risk/reward tilts modestly positive at this price.

I applied a 13.0x multiple to FMP consensus forward EPS of $1.381—a modest premium to HBAN's 5-year average P/E of 12.41x, justified by roughly 12% expected EPS growth and good accrual quality, but capped by 9% ROE and negative ROIC. That yields $17.95. I intentionally used the FMP consensus EPS rather than the research brief's $1.90 guidance because that guidance is inconsistent with reported 2026 quarterly EPS.